One Case of Heart Failure Caused by Osimertinib Mesylate Tablets

doi:10.19803/j.1672-8629.20240786

Abstract

Abstract: Objective To analyze the clinical characteristics and potential mechanisms of heart failure caused by osimertinib mesylate tablets (osimertinib) in order to provide a reference for safe use of osimertinib and for clinical management. Methods The clinical data of a 59-year-old patient with lung adenocarcinoma who developed heart failure after taking osimertinib was analyzed. Combined with related literature, the Naranjo's score was used to find out about the drugs that might have caused heart failure, causes of occurrence, and measures for prevention and treatment. Results It was very likely that osimertinib caused heart failure in this patient. After discontinuation of osimertinib and management of heart failure, the patient's cardiac function significantly improved. Conclusion Despite the scarcity of cases of heart failure caused by osimertinib, clinicians should be aware that osimertinib can cause heart failure a few days to several months after administration.

Key words: Osimertinib Mesylate Tablets, Heart Failure, Lung Adenocarcinoma, Adverse Drug Reactions

CLC Number:

KONG Yingli, XIN Xinyuan, SHI Huihui, ZHAO Zinan, ZHANG Yatong. One Case of Heart Failure Caused by Osimertinib Mesylate Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1300-1303.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240786

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I11/1300

References

[1] LEITER A, VELUSWAMY RR, WISNIVESKY JP.The Global Burden of Lung Cancer: Current Status and Future Trends[J]. Nature Reviews Clinical Oncology, 2023, 20(9): 624-639.
[2] RICOTTI A, SCIANNAMEO V, BALZI W, et al.Incidence and Prevalence Analysis of Non-Small-Cell and Small-Cell Lung Cancer Using Administrative Data[J]. International Journal of Environmental Research and Public Health, 2021, 18(17): 9076.
[3] MOK TS, WU YL, AHN MJ, et al.Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J]. The New England Journal of Medicine, 2017, 376(7): 629-640.
[4] ZHANG CH, CUI XK, PENG TT, et al.Efficacy and Safety of Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer: a Meta-Analysis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(2): 178-183.
[5] SORIA JC, OHE Y, VANSTEENKISTE J, et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. The New England Journal of Medicine, 2018, 378(2): 113-125.
[6] FU ZL, SUN HY.Literature Review of Osimertinib-Associated Heart Failure[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2023, 32(9): 673-678.
[7] KUNIMASA K, KAMADA R, OKA T, et al.Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated with Osimertinib[J]. JACC CardioOncol, 2020, 2(1): 1-10.
[8] PATEL K, HSU KY, LOU K, et al.Osimertinib-Induced Biventricular Cardiomyopathy with Abnormal Cardiac MRI Findings: a Case Report[J]. Cardiooncology, 2023, 9(1): 38.
[9] LU SX, XING YL, MIAO Y, et al.Osimertinib Induced Adverse Cardiac Events: a CaseReport[J]. Journal of Geriatric Cardiology, 2023, 20(9): 702-706.
[10] ANANDK, ENSOR J, T RACHTENBER GB, et al. Osimertinib-Induced Cardiotoxicity: a Retrospective Review of the FDA Adverse Events Reporting System (FAERS)[J]. JACC Cardio Oncol, 2019, 1(2): 172-178.
[11] FU XW.Literature Analysis of Osimertinib Adverse Reactions[J].Tianjin Pharmacy(天津药学), 2022, 34(4): 47-49, 54.
[12] LOU AQ, ZHENG JC.Risk Analysis of Cardiotoxicity from Osimertinib Based on FAERS[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2022, 25(9): 788-792.
[13] DONG SC, HUO XD, SUN C, et al.Based on Real-World Monitoring Data to Explore and Analyze the Adverse Reaction Signals of Osimertinib after Marketing[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(6): 642-646.
[14] WANG L, ZHANG L, ZHU LN, et al.Research Progress of Osimertinib Related Cardiotoxicity[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2023, 43(13): 1516-1520.
[15] NARANJO CA, BUSTO U, SELLER SEM, et al.A Method for Estimating the Probability of Adverse Drug Reactions[J]. Clinical Pharmacology and Therapeutics,1981, 30(2): 239-245.
[16] BABAR T, BLOMBERG C, HOFFNER E, et al.Anti-HER2 Cancer Therapy and Cardiotoxicity[J]. Current Pharmaceutical Design, 2014, 20(30): 4911-4919.
[17] LIU S, LI S, HAI J, et al.Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib[J]. Clinical Cancer Research, 2018, 24(11): 2594-2604.
[18] SHYAM SS, SHARMA UC, POKHAREL S.Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 262.
[19] GOMEZ JA.Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors: Novel Mechanisms, Predictors of Hypertension and Management Strategies[J]. American Heart Journal Plus, 2022, 17: 100144.
[20] BYUN JY, HAN S, LIU Y, et al.Sex-Specific Risk of Heart Failure and Acute Myocardial Infarction Associated with Osimertinib in Older Patients with Non-Small Cell Lung Cancer[J]. Therapeutic Advances in Medical Oncology, 2024, 16: 17588359241264721.
[21] MADONNA R, PIERAGOSTINO D, CUFARO MC, et al.Sex-Related Differential Susceptibility to Ponatinib Cardiotoxicity and Differential Modulation of the Notch1 Signalling Pathway in a Murine Model[J]. Journal of Cellular and Molecular Medicine, 2022, 26(5): 1380-1391.
[22] LYON AR, LÓPEZ-FERNÁNDEZ T, COUCH LS, et al. 2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association(EHA), the European Society for Therapeutic Radiology and Oncology(ESTRO) and the International Cardio-Oncology Society(IC-OS)[J]. European Heart Journal, 2022, 43(41): 4229-4361.
[23] MIZUNO T, SAKAI T, TANABE K, et al.Identification of Target Small Molecule Tyrosine Kinase Inhibitors that Need Monitoring and Clinical Application of Protocol for Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction Using Signal Detection: An Investigation of Real World Data[J]. Journal of Oncology Pharmacy Practice, 2021, 27(4): 804-814.
[24] XU WJ, PENG Q, HUANG HY, et al.285 Cases of Adverse Drug Reactions Related to New Antineoplastic Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(2): 199-203, 210.